With the exception of specific mutations for atypical hemolytic uremic syndrome (aHUS) [8] and focal segmental glomerulosclerosis (FSGS) [9], and anti-PLA2R [10] and anti-thrombospondin type 1 [11] autoantibodies for membranous nephropathy (MN), no clear genetic, epigenetic or environmental risk factors have been identified to predict the risk of recurrence [12]. This evidence concerns the gene PLA2R1 and focal segmental glomerulosclerosis.